Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive tumor type with high mortality. One promising approach for SCLC treatment would be to utilize agents targeting molecular abnormalities regulating resistance to apoptosis. BH3 mimetic antagonists, such as ABT-737 and its orally available derivative ABT-2...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Biol Ther
Auteurs principaux: Nakajima, Wataru, Sharma, Kanika, Hicks, Mark A., Le, Ngoc, Brown, Rikiara, Krystal, Geoffrey W., Harada, Hisashi
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2015
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4847809/
https://ncbi.nlm.nih.gov/pubmed/26575826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1108485
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires